Skip to main content

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial

Publication ,  Conference
Gibson, CM; Korjian, S; Tricoci, P; Daaboul, Y; Alexander, JH; Steg, PG; Lincoff, AM; Kastelein, JJ; Mehran, R; D'Andrea, D; Merkely, B ...
Published in: CIRCULATION
December 20, 2016

Duke Scholars

Published In

CIRCULATION

EISSN

1524-4539

ISSN

0009-7322

Publication Date

December 20, 2016

Volume

134

Issue

25

Start / End Page

E706 / E706

Location

New Orleans, LA

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gibson, C. M., Korjian, S., Tricoci, P., Daaboul, Y., Alexander, J. H., Steg, P. G., … Harrington, R. A. (2016). The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. In CIRCULATION (Vol. 134, pp. E706–E706). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
Gibson, C Michael, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, John H. Alexander, Philippe G. Steg, A. M. Lincoff, et al. “The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial.” In CIRCULATION, 134:E706–E706. LIPPINCOTT WILLIAMS & WILKINS, 2016.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, et al. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2016. p. E706–E706.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D’Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2016. p. E706–E706.

Published In

CIRCULATION

EISSN

1524-4539

ISSN

0009-7322

Publication Date

December 20, 2016

Volume

134

Issue

25

Start / End Page

E706 / E706

Location

New Orleans, LA

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology